ARCH Venture Partners

Activity in this selectionJun 30, 2026 · Jun 1, 2026

By stage

Series B3

Biotech3

United States3

3 in this selection

Jun 24

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jun 8

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

$99.5MSeries B

Role not disclosed